Results 21 to 30 of about 6,658 (202)

A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy. [PDF]

, 2022
Introduction: Radioligand therapy (RLT) is an expanding field that has shown great potential in the fight against cancer. Radionuclides that can be carried by selective ligands such as antibodies, peptides, and small molecules targeting cancerous cells ...
Gemma, Dias, Veronique, Gouverneur, Bart, Cornelissen, Michael, Mosley, Gianluca, Destro, Claudia, Fraser, Chung Ying, Chang, Florian, Guibbal, Zijiun , Chen   +8 more
core   +2 more sources

PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. [PDF]

PLoS ONE, 2013
Exposure to genotoxic agents, such as irradiation produces DNA damage, the toxicity of which is augmented when the DNA repair is impaired. Poly (ADP-ribose) polymerase (PARP) inhibitors were found to be "synthetic lethal" in cells deficient in BRCA1 and ...
Payel Chatterjee, Gaurav S Choudhary, Arishya Sharma, Kamini Singh, Warren D Heston, Jay Ciezki, Eric A Klein, Alexandru Almasan   +7 more
doaj   +1 more source

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib

Clinical Pharmacokinetics, 2022
Rucaparib is an oral small-molecule poly(ADP-ribose) polymerase inhibitor indicated for patients with recurrent ovarian cancer in the maintenance and treatment settings and for patients with metastatic castration-resistant prostate cancer associated with a deleterious BRCA1 or BRCA2 mutation.
Mingxiang Liao, Jeri Beltman, Heidi Giordano, Thomas C. Harding, Lara Maloney, Andrew D. Simmons, Jim J. Xiao   +6 more
openaire   +2 more sources

Copper-Mediated Radiosynthesis of [18F]Rucaparib

, 2021
The poly­(ADP-ribose) polymerase (PARP) inhibitor rucaparib is used in the clinic to treat BRCA-mutated cancers. Herein, we report two strategies to access the 18F-isotopologue of rucaparib by applying a copper-mediated nucleophilic 18F ...
Gianluca Destro (6166061), Florian Guibbal, Véronique Gouverneur, Zijun Chen (286584), Bart Cornelissen, Chung Ying Chan (11355308), Véronique Gouverneur (1300443), Zijun Chen, Chung Ying Chan, Bart Cornelissen (339544), Gianluca Destro, Florian Guibbal (6588116)   +11 more
core   +1 more source

Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells

Medical Sciences, 2022
Ovarian cancer accounts for 3% of the total cancers in women, yet it is the fifth leading cause of cancer deaths among women. The BRCA1/2 germline and somatic mutations confer a deficiency of the homologous recombination (HR) repair pathway.
Olivia El Naggar, Brenna Doyle, Kelsey Mariner, Susan K. Gilmour   +3 more
doaj   +1 more source

Pharmacological Poly (ADP-Ribose) Polymerase Inhibitors Decrease Mycobacterium tuberculosis Survival in Human Macrophages

Frontiers in Immunology, 2021
Diabetes mellites (DM) is correlated with increased susceptibility to and disease progression of tuberculosis (TB), and strongly impairs effective global TB control measures.
Cassandra L. R. van Doorn, Sanne A. M. Steenbergen, Kimberley V. Walburg, Tom H. M. Ottenhoff   +3 more
doaj   +1 more source

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer

Frontiers in Oncology, 2020
Purpose: PARP inhibitors are a novel targeted anti-cancer drug and a large number of clinical studies on PARP inhibitors have been accomplished. This updated meta-analysis was conducted to evaluate the efficacy and safety of PARP inhibitors in advanced ...
Yifan Jiang, Juan Zhao, Li Zhang, Sijuan Tian, Ting Yang, Li Wang, Minyi Zhao, Qing Yang, Yaohui Wang, Xiaofeng Yang   +9 more
doaj   +1 more source

Drug Monographs: Olaratumab and Rucaparib [PDF]

Hospital Pharmacy, 2017
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases ...
Dominic A, Solimando, J Aubrey, Waddell
openaire   +2 more sources

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring

Pharmaceutics, 2023
Poly (ADP-ribose) polymerase inhibitors (PARPis) are becoming increasingly meaningful in oncology, and their therapeutic drug monitoring (TDM) might be beneficial for patients. Several bioanalytical methods have been reported for PARPis quantification in
Giovanni Canil, Marco Orleni, Bianca Posocco, Sara Gagno, Alessia Bignucolo, Marcella Montico, Rossana Roncato, Serena Corsetti, Michele Bartoletti, Giuseppe Toffoli   +9 more
doaj   +1 more source

Evaluation of phototoxicity induced by the anticancer drug rucaparib [PDF]

Scientific Reports, 2022
AbstractRucaparib (RCP) is a potent selective inhibitor of both PARP-1 and PARP-2 enzymes that induces synthetic lethality in cancer cells. It is used for the treatment of breast and ovarian tumors harboring deleterious germline or somatic cancer susceptibility genes mutations.
Alejandro Mateos-Pujante, María Consuelo Jiménez, Inmaculada Andreu   +2 more
openaire   +5 more sources